The relative acute hypoglycaemic potencies of IGF-I and several variants of IGF-I which bind poorly to the IGF-I binding proteins (IGFBPs) have been examined in marmosets (Callithrix jacchus) and the pig. In the marmoset study, IGF-I and des(1-3)IGF-I were compared in anaesthetised and conscious animals in a range of bolus doses from 42 to 270 µg/kg body weight. In the pig study, IGF-I was compared with four variants, des(1-3)IGF-I, long-IGF-I, R 3 IGF-I and long-R 3 IGF-I (LR 3 IGF-I), which show reduced affinity for the IGFBPs as well as with insulin. Doses in the pig were 20 and 50 µg/kg body weight for the IGFs and 3 µg/kg for insulin. In each study serial blood samples were taken from 30 min before to 4 h after the bolus injection.
Introduction
The insulin-like hypoglycaemic effects of insulin-like growth factor-I (IGF-I) have been demonstrated in a number of species including rats, mice, dogs, pigs, monkeys and humans (e.g. Guler et al. 1987 , Jacob et al. 1989 , Walton et al. 1989 , Bodkin et al. 1991 . Whereas the actions of IGF-I are similar to those of insulin in so far as glucose disappearance (uptake by tissues) is increased ( Jacob et al. 1989) and appearance (production) is decreased (Moxley et al. 1990 ), the potency is very much lower (Tominaga et al. 1995) with effects on glucose disappearance being more pronounced than those on appearance. The latter difference reflects the tissue distribution of type 1 receptors through which IGF-I actions occur. IGF-I can also bind to the insulin receptor but with much lower affinity (Zapf et al. 1978 , Czech 1985 . Very high concentrations of IGF-I, such as those in the studies of Walton et al. (1987) and Boulware et al. (1992) where free IGF-I exceeded insulin by about 100-fold or more, would be needed for substantial signalling to occur via this receptor. Because of the dearth of type 1 receptors in hepatic tissue (the major site of glucose production) and adipose tissue (a site of glucose disappearance), any actions of IGF-I on substrate metabolism in these tissues is usually considered to be via insulin receptors. In fact, these tissues are generally considered insensitive to IGF-I.
IGF-I also differs from insulin in that the normal counter-regulatory responses to the induced hypoglycaemia are altered. This is largely attributed to the direct or indirect suppression of pancreatic secretion of glucagon by IGF-I (e.g. Laager et al. 1993 , Furnsinn et al. 1994 , Trainer et al. 1994 . IGF binding proteins (IGFBPs) are also important in modulating the hypoglycaemic actions of IGF-I. Infusion of the IGF-I/ IGFBP-3 complex or co-infusion of IGFBP-1 with IGF-I abolishes the hypoglycaemic effects of IGF-I (Lewitt et al. 1991 , Clark et al. 1993 . The combined effects of differing receptor tissue distribution and affinities for insulin and IGF-I, binding of IGF-I by the IGFBPs and suppression of the hypoglycaemia counterregulatory responses by IGF-I lead to a more prolonged hypoglycaemic response to IGF-I (e.g. Elahi et al. 1993) .
IGF-I has been shown to be of potential therapeutic benefit in diabetic states as insulin resistance and insulin requirement are reduced by its administration (Schoenle et al. 1991 , Hussain et al. 1993 . We have compared the hypoglycaemic effects of IGF-I and several IGF-I analogues, which have low affinity for IGFBPs, in marmosets and pigs. This has allowed the role of the IGFBPs in modulating the hypoglycaemic actions of IGF-I to be examined with the view to assessing the potential therapeutic role for the IGF analogues. Binding to the IGFBPs appears to limit the hypoglycaemic efficacy of IGF-I given by bolus injection.
Materials and Methods

Peptides
Recombinant human IGF-I and des(1-3)IGF-I were provided by Genentech Inc. (South San Francisco, CA, USA) and recombinant human R 3 IGF-I, long-R 3 IGF-I (LR 3 IGF-I) and long-IGF-I by GroPep Pty Ltd (Adelaide, SA, Australia). The R 3 variants have arginine substituted for glutamate at position 3 (Francis et al. 1992 ) and show greatly reduced affinity for binding to IGFBPs, especially in rats (Francis et al. 1992 , Lord et al. 1994 . The long-IGF-I has an N-terminal extension peptide attached but no other changes to the IGF-I molecule and has intermediate binding affinities to the type 1 receptors and IGFBPs (Francis et al. 1992) . The IGF peptides were dissolved and diluted as required in 20 m sodium acetate. Peptides were administered to animals via an indwelling intravenous catheter as a single bolus injection.
Experimental design
Marmoset experiments
The common marmoset (Callithrix jacchus) is a small arboreal non-human primate which has been widely used in biomedical research as a model for humans (Clarke 1994) . Marmosets of about 350 g body weight were obtained from the CSIRO Division of Human Nutrition (Adelaide, Australia) where they were housed in family groups and fed a customformulated extruded diet supplemented with fresh fruit ( J Clarke, unpublished data). Each marmoset was surgically prepared under aseptic conditions with an indwelling catheter (Dural Plastics, SV37 tubing, 0·50 mm i.d., 1·00 mm o.d.) in the right femoral vein. Prior to surgery each animal was anaesthetised with an i.m. injection of 0·7-1·0 ml Saffan (Pitman Moore Australia Pty Ltd, Sydney, Australia). The catheter was tunnelled under the skin to emerge in the mid-scapular region where it was secured, filled with heparinised saline (1000 U/ml) and sealed. At least two days recovery from surgery was allowed before experiments were performed.
Injection protocol There were two experiments which differed principally in whether the marmosets were anaesthetised (experiment 1) or not (experiment 2) during the test procedures. Marmosets were not fasted overnight but were removed from their cages before the morning feeding. In experiment 1 the marmosets were anaesthetised with Saffan via the catheter and kept warm on a heated pad. Anaesthesia was maintained as required by further intravenous injections of Saffan as required. Thirty minutes after induction of anaesthesia three blood samples were removed at 10-min intervals and then the selected IGF treatment injected via the catheter. Blood samples (about 200 µl) were then taken at 10, 20, 30, 45, 60, 90, 120, 150, 180 and 240 min following IGF injection and placed in heparinised tubes. Samples were immediately centrifuged, the plasma removed and frozen, and the red cells resuspended in sterile saline for return to the animal after the next blood sample. Upon completion of sampling and after regaining consciousness the marmosets were returned to the cage. Two complete days were allowed between experiments on the same animal.
Similar procedures were used in experiment 2 except that the conscious marmosets were kept in their cage and caught and manually restrained for each blood sample.
Treatments Treatment groups for experiment 1 were as follows: excipient control; IGF-I at doses of 50, 87·5, 153 and 270 µg/kg body weight; des(1-3)IGF-I at doses of 41·5, 72·8, 127 and 225 µg/kg body weight. These doses were chosen on the basis of relative potencies observed in a preliminary trial and were expected to induce a comparable range of hypoglycaemic responses over the dose range. For experiment 2 there were three treatments: excipient, IGF-I (153 µg/kg body weight) and des(1-3)IGF-I (127 µg/kg body weight). These doses were chosen on the basis of results from the anaesthetised marmosets.
Experimental design For experiment 1 there were 9 treatments and 18 marmosets, with each treatment replicated 6 times. Each marmoset received 3 treatments. The experiment was designed as a randomised triple lattice with 2 replicates. For experiment 2 there were 3 treatments and 6 marmosets with each animal receiving each treatment once. The experiment was designed as a 3 3 Latin square replicated once with random allocations of treatments, animals and time but constrained to a different treatment sequence in each square.
Pig experiments Large-white male pigs of 55 kg body weight were obtained from the Animal Research Laboratories, Werribee, and surgically fitted with an indwelling catheter in the jugular vein (Dunshea & King 1995) . The pigs were housed in individual pens and fed a custom grower diet (20% crude protein, 1% lysine, 14·5 MJ/kg digestible energy) during the experimental period with free access to water via a nipple drinker. Pigs were fed 2·6 kg/day in two equal feeds at 0700 and 1630 h.
Injection protocol For the duration of the study each pig was housed in an individual pen. The selected treatment was delivered as a bolus via the jugular catheter at 1000 h. Blood samples were taken at 60, 30, 15 and 1 min (time zero) before each injection followed by further samples at 2·5, 5, 10, 15, 20, 30, 45, 60, 90, 120 and 240 min after the bolus injection.
Treatments Treatment groups were as follows: excipient control (100 m acetic acid); insulin (3 µg/kg body weight); each of IGF-I, des(1-3)IGF-I, R 3 IGF-I, long-IGF-I and LR 3 IGF-I at 20 and 50 µg/kg body weight.
Experimental design
The experiment was designed as a randomised rectangular lattice. There were 12 treatments and 8 pigs, with each treatment replicated 4 times. Each pig received one of six treatments on Monday, Wednesday and Friday of two consecutive weeks.
The experimental protocols followed the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes, and were approved by the Animal Experimentation Ethics Committees of the CSIRO Division of Human Nutrition and the Victorian Institute of Animal Science.
Analytical methods
Plasma glucose was measured using a Cobas analyser (Roche Diagnostica, Nutley, NJ, USA). Determinations of IGF-I and IGFBP activity in plasma by direct RIA or interference in the RIA assay respectively, have been described by Tomas et al. (1991) who also presented data showing the activity of IGFBP in the RIA assay was consistent with Western ligand blot analysis. Des(1-3)IGF-I is underestimated by around 30% in the IGF-I assay due to different binding characteristics in the assay (Tomas et al. 1996b) . The intra-and interassay coefficients of variation (C.V.) for the IGF-I assay were <5% and <10% respectively. Plasma insulin in marmoset plasma was measured with an RIA kit (Insulin-CT, CIS, Bio International, Gif sur Yvette, Cedex, France) with claimed intra-and interassay C.V. values of between 5 and 10%. Competitive binding of IGF-I and variants to a mixture of IGFBPs in porcine plasma and to purified porcine IGFBP-3 was measured in vitro essentially as described by Szabo et al. (1988) . Plasma amino acid concentrations in pig plasma were determined by an automated HPLC method using pre-column derivatisation with 9-fluorenylmethyl chloroformate (FMOC) (Haynes et al. 1991) .
Calculations and statistical methods
The depression in plasma glucose was integrated over time by calculating the area under the curve (AUC) using a trapezoidal summation method (SigmaPlot, Jandel Scientific, San Raphael, CA, USA). Where plasma glucose levels for a particular treatment had not returned to baseline within the chosen period of integration (120 min or 240 min after the bolus injection of IGF) the AUC was only partial but was considered a valid indicator of comparative potency within the chosen time-frame.
Values are presented as means ... Significance of between-treatment effects was assessed by analysis of variance, with P<0·05 taken as the level of statistical significance. Multiple comparisons among treatment means were made using either Tukey's test or adjusted t values using the Bonferroni principle for multiple comparisons.
Results
Plasma glucose changes
There was an immediate fall in plasma glucose concentrations in both marmosets and pigs in response to a bolus injection of IGF with the nadir occurring 20-30 min after injection (Figs 1 and 2) . In anaesthetised marmosets the nadir was linearly related to IGF-I dose (r 2 =0·97, P<0·001) down to 2·45 0·28 m at 270 µg IGF-I/kg body weight. With des(1-3)IGF-I the nadir was also linearly related to dose to a maximal 2·47 0·14 m at only 127 µg des(1-3)IGF-I/kg body weight (r 2 =0·97, P<0·001) and the higher dose of 225 µg/kg did not cause further lowering of plasma glucose. The slopes for these dose-responses showed des(1-3)IGF-I to be twofold more potent than IGF-I for the initial glucose lowering effect for doses less than 153 µg/kg ( 0·20 vs 0·10 respectively; P<0·01). The higher relative potency of des(1-3)IGF-I was not a specific effect of anaesthesia since this effect was also evident in conscious marmosets. The difference in potency was retained despite a progressive decline of 2·5 m over three hours in the plasma glucose levels of the control group of conscious marmosets. This decline, and the higher variability of observations from conscious rather than anaesthetised marmosets, may be related to the unavoidable stress arising from the repeated capture and restraint of these nervous animals during sampling.
The nadir in plasma glucose in the pig was also related to the dose of IGF (P<0·001). Average nadir values for 20 and 50 µg/kg doses were 0·9, 1·1, 2·8, 2·8, 3·4 and 2·5, 2·9, 3·3, 3·6, 4·6 m for IGF-I, long-IGF-I, R 3 IGF-I, LR 3 IGF-I and des(1-3)IGF-I respectively (pooled ..=0·38). All except 20 µg/kg IGF-I and long-IGF-I differed from controls ( 0·3 m; P<0·01). The nadir induced by R 3 IGF-I, LR 3 IGF-I or des(1-3)IGF-I was significantly lower than that for either IGF-I or long-IGF-I (P<0·001) but there were no differences between IGFs within these two groupings.
The differences in potency are more clearly illustrated when the hypoglycaemic effect is integrated as the area under the curve (Fig. 3) . Comparisons between marmosets and pigs show similar hypoglycaemic efficacy for IGF-I when the doses are expressed per body weight 0·75 but des(1-3)IGF-I appears to be about twofold more potent in the pig. The R 3 variants were intermediate to IGF-I and des(1-3)IGF-I for potency in the pig. The data in Fig.  3 show that the relative difference between the AUC curves for IGF-I and des(1-3)IGF-I increases as the time of integration is extended. This is a clear illustration of the more prolonged hypoglycaemic action of des(1-3)IGF-I (and also of the R 3 variants in the pig) compared with IGF-I. However, the variability of the AUC data is increased as the time period is extended beyond two hours due both to the fewer sampling points and to the more varied rate of recovery to euglycaemia by individual animals. Nonetheless, except for IGF-I in the pig, there was a significant dose-response for all peptides over each of the integration times.
Plasma amino acids were measured in samples taken 30 min after bolus IGF injection in the pig. Data for six dietary indispensable amino acids including the three branched chain amino acids show a significant doserelated reduction in their concentrations in plasma following IGF treatment compared with the control (P<0·001; Fig. 4 ). Unlike the effects seen for plasma glucose at the same time point, there was no consistent difference in potency for amino acid lowering between the IGFs. However, we note that the 50 µg/kg dose of LR 3 IGF-I was significantly (P<0·001) more potent than any of the other IGFs at either dose. Whereas increasing the dose of IGFs other than LR 3 IGF-I from 20 to 50 µg/kg lowered the plasma amino acids, on average, a further 0·6-fold (P<0·001), the equivalent change in LR 3 IGF-I dosage caused a further 3·3-fold lowering (peptide dose interaction, P<0·001). This potent action of LR 3 IGF-I on plasma amino acids is distinct from its relative hypoglycaemic effects.
We examined whether differential changes in plasma levels of IGF-I, IGFBPs or insulin may have contributed to the extended hypoglycaemic effect of des(1-3)IGF-I in marmosets. The limited sample size available from these animals restricted assays to samples of plasma pooled within treatment groups. Treatments and time points assayed were chosen on the basis of the observed hypoglycaemic effects. No statistical analysis was possible but the data (Fig.  5) indicate that injection of des(1-3)IGF-I did not lead to a prolonged elevation of IGF-I levels or to a suppression of IGFBP activity levels compared with IGF-I. Likewise, plasma insulin levels were lowest in the des(1-3)IGF-Itreated marmosets, rather than highest if these were to account for the prolonged hypoglycaemia.
The relative affinity with which the IGF-I variants used in the pig study bound to proteins in porcine plasma and to purified IGFBP-3 in vitro were determined in order to ascertain whether the hypoglycaemic response was related to the degree of competition for binding between IGF-I receptors and the circulating binding proteins. Except for LR 3 IGF-I the binding patterns of the IGFs for plasma proteins and for purified IGFBP-3 were broadly comparable. Only IGF-I and long-IGF-I showed appreciable competition for labelled IGF-I binding (Fig. 6) with the binding affinity of long-IGF-I about an order of magnitude less than that of IGF-I. The similar binding profiles and the apparently higher binding affinity for IGFBP-3 relative to plasma suggest that IGFBP-3 is the principal binding protein for all the IGFs except LR 3 IGF-I. 
Discussion
These results from the marmoset and the pig clearly demonstrate that variants of IGF-I which show reduced affinity for IGFBPs also show substantially higher hypoglycaemic potency when delivered as a bolus dose. The data from the pig study show that the hypoglycaemic potency was inversely related to the affinity of the IGF for IGFBPs. This supports and extends the findings of Lewitt et al. (1991) and Clark et al. (1993) who showed that IGFBPs, whether administered separately or complexed with IGF-I, can attenuate the hypoglycaemic actions of intravenously injected IGF-I in rats. In our study, it is likely that the lower affinity of the variants for IGFBPs would lead to their concentrations being higher than would occur with IGF-I in the vicinity of the receptors (Ballard et al. 1989 , Zapf 1995 . Thus, the increased potency may be simply ascribed to a greater availability of the variants for binding to the IGF-I receptor. This notion is further supported by the linear dose-response of the nadir in plasma glucose for a range of doses up to 270 µg/kg IGF-I and 127 µg/kg des(1-3)IGF-I in the marmoset. The lack of a further lowering of the nadir by the highest dose of 225 µg/kg des(1-3)IGF-I suggests either that the receptors were fully occupied at the lower dose or that some other mechanism limited the response.
The overall hypoglycaemic effect encompasses both the nadir in plasma glucose levels and the duration of the hypoglycaemia and is measured as the cumulative change in plasma glucose levels expressed as the AUC. These measurements have revealed two key findings. First, des(1-3)IGF-I and the R 3 -substituted IGFs cause a more prolonged hypoglycaemia than does IGF-I. Secondly, the sustained hypoglycaemia is not simply related to the relative nadir in plasma glucose. Thus other factors which are differentially affected by these IGFs must be operating. The short half-lives of the analogues in the plasma , Bastian et al. 1993 would argue against a sustained maintenance of an effective concentration of these peptides as compared with IGF-I. Certainly we saw no evidence for a sustained increase in plasma IGFs following des(1-3)IGF-I injection to marmosets, albeit we could not distinguish between des(1-3)IGF-I and IGF-I in our assay. Nor could differential changes in total IGFBP binding activity or insulin levels be invoked to explain the prolonged hypoglycaemia following des(1-3)IGF-I treatment. With regard to the IGFBPs, the analogues (except long-IGF-I) would, of course, be relatively unaffected by any changes. It could be argued that a substantial increase in certain IGFBPs, such as IGFBP-I, could reduce tissue concentrations of IGF-I and reduce its potency relative to the analogues. However, in both the pig and the marmoset, differences between IGFs in the rate of recovery from hypoglycaemia were apparent within 30-40 min of injection which suggests that changes in the pattern of IGFBP distribution are unlikely to be a major factor determining the prolonged potency of the analogues. IGFs are known to suppress the secretion of several glucoregulatory hormones including insulin and glucagon (Zenobi et al. 1992 , Laager et al. 1993 , Furnsinn et al. 1994 . Our data from marmosets indicates that des(1-3)IGF-I appears to suppress plasma insulin levels to a greater extent than does IGF-I. A similar differential suppression of glucagon levels seems a likely important factor in the slower return to euglycaemia. We were unable to test this view here since our blood collection procedures provided unsuitable plasma samples for glucagon assays.
The principal path for glucose lowering by IGFs is via enhanced uptake of glucose to peripheral tissues ( Jacob et al. 1989 , Dimitriadis et al. 1992 , Laager et al. 1993 , the suppression of glucose production playing a lesser role. This is generally attributed to the lack of type 1 receptors in hepatic tissues (Caro et al. 1988) . A contributing factor to the prolonged hypoglycaemia following treatment with des(1-3)IGF-I, LR 3 IGF-I and R 3 IGF-I may be that the concentrations of free peptides in hepatic tissue reach levels sufficient to act via the insulin receptor as well as the IGF-I receptor. Ballard et al. (1994) argued that the IGFs would probably never act via the insulin receptor largely due to their low affinity for that receptor, about 2-3 orders of magnitude lower than is the case for insulin (Czech 1985) . However, the 'instantaneous' concentrations of des(1-3)IGF-I reached in the extracellular fluid directly after injection of 225 µg des(1-3)IGF-I/kg could be as high as 1100 ng/ml, which could be the equivalent of 1 to 10 ng/ml insulin for binding to the insulin receptor. This encompasses the range necessary to elicit an insulin response. Thus, it is possible that the analogues were able to suppress hepatic glucose production by activating the insulin receptors. One consequence could be a delayed recovery from the hypoglycaemia compared with IGF-I. In the pig study, we estimate that peak des(1-3)IGF-I levels would have been much lower than in the marmosets, around 250 ng/ml (0·25 to 2·5 ng/ml insulin 'equivalence'). In fact, Walton et al. (1989) measured average peak levels of 1019 ng/ml IGF-I (95% unbound) in the plasma of pigs following a bolus injection of around 100 µg IGF-I/kg body weight, twice the dose used in this study. In addition, the pig is also relatively sensitive to insulin (Pethick & Dunshea 1996) and this may extend to IGF-I actions via the insulin receptor. It is interesting that, in humans, a dose of IGF-I which raised 'free' IGF-I to 27 ng/ml, and had equal biopotency with insulin levels of around 1 ng/ml plasma for glucose uptake, was also equally effective in the inhibition of hepatic glucose output . Also, glucose metabolism by the pig liver is particularly sensitive to insulin and it is reasonable to expect that it would also be more sensitive to IGF-I acting via the insulin receptor. It must also be borne in mind, however, that hepatic tissues from species other than the rat and human may not be free of IGF-I receptors and also that insulin itself did not produce a prolonged hypoglycaemia in the pig (see Fig. 2 ). Nonetheless, while the experimental conditions between studies differed, the results obtained by others in humans indicate that inhibition of hepatic glucose output may have been a factor contributing to the extended hypoglycaemia following the administration of the potent IGF-I analogues in our experiments.
We note that although LR 3 IGF-I appears to bind to IGFBPs with even lower affinity than does des(1-3)IGF-I (Fig. 6) , it has a lower hypoglycaemic potency in the pig. This is similar to the response noted by Francis et al. (1992) in studies on metabolic effects of the peptides on chicken embryo fibroblast cells in vitro. The activation of the IGF-I receptor by IGF binding is determined both by the level of available ('free') IGF and the affinity of the IGF for the receptor. Thus the potency of the IGF is determined by the balance between its relative affinity for the binding proteins and the receptors. While des(1-3)IGF-I binds to the IGF-I receptor with equal affinity to IGF-I, the affinity for LR 3 IGF-I binding to the IGF-I receptor is reduced about fourfold (Francis et al. 1992) . This difference in receptor affinity results in relatively higher binding of des(1-3)IGF-I than LR 3 IGF-I (Bastian et al. 1993 ) and would explain the higher potency of des(1-3)IGF-I.
The reduction in plasma amino acids following IGF injection is consistent with a number of reports for the rat ( Jacob et al. 1989) , dog (Roth et al. 1993 , Giacca 1994 ) and human (Boulware et al. 1992 , Elahi et al. 1993 ). This effect is generally subscribed to reduced proteolysis in muscle tissue, a view supported by data from IGF-I infusions to isolated limbs (Fryburg 1994 , Oddy & Owens 1996 but may also be due, in part, to increased rates of protein synthesis (Russell-Jones et al. 1994) . The anomalous potent response to the high dose of LR 3 IGF-I is difficult to explain, particularly in view of the relative ranking of the IGFs for hypoglycaemic potency. The substitution of arginine at position 3 from the N-terminus of the IGF molecule does not appear to be responsible since the R 3 -IGF-I peptide caused the lowest average lowering effect at each of the doses. Likewise, long-IGF-I does not show the anomalous behaviour which indicates that the N-terminal extension of 11 amino acids is not specifically involved. Studies on isolated limbs to compare the effects of des(1-3)IGF-I and LR 3 IGF-I are needed to determine whether the apparent differential response to LR 3 IGF-I is due to a local effect on muscle tissues or arises from differential effects on other components of the endocrine system.
IGF-I may have a potential role in the control of both insulin-dependent and non-insulin-dependent diabetes due to its hypoglycaemic actions via the IGF-I receptor and its ability to enhance insulin responsiveness in insulinresistant states (Zenobi et al. 1992 , Hussain et al. 1993 , Kuzuya et al. 1993 , Bach et al. 1994 , Froesch & Hussain 1994 , Dunger et al. 1995 . We have previously reported that des(1-3)IGF-I was more potent than IGF-I and can facilitate the glucoregulatory action of a low dose of insulin when infused conjointly to diabetic rats (Tomas et al. 1996a) . The evidence presented here for a more prolonged hypoglycaemic action of IGF-I variants which have low affinity for the IGFBPs also point to their possible superior efficacy over IGF-I in these situations, particularly since the data were obtained in animal models of accepted relevance to humans. Since the more rapidly cleared variants of IGF-I can remain more potent than IGF-I even when administered by injection rather than continuous infusion (Tomas et al. 1996b) , their potential usefulness in the clinical control of diabetes warrants their further comparison in non-rodent diabetic animal models.
